Region Genetic Association Analysis of Breast Cancer Patients With and Without Persistent Postsurgical Neuropathic Pain,” published in the March 2025 issue of European Journal of Pain by Mustonen et ...

The FLAMINGO-01 DSMB met twice in 2024, most recently in December 2024, and recommended to continue the study as is without modification. No serious adverse events related to GLSI-100 have been ...

The trial’s first phase will begin in university hospitals across the Netherlands, Denmark, Germany and Sweden.

European regulators have cleared Anocca to begin a Phase I/II umbrella trial of its lead targeted T-cell receptor (TCR) therapy ANOC-001 and other pipeline candidates in certain advanced pancreatic ...

The optimal allogeneic dendritic cell for stimulating self MHC-restricted anti-tumor responses is probably one that is incompatible at one HLA-DR allele with the patient (for direct ...

Image Credit: CI Photos/Shutterstock.com Immune checkpoint inhibitors, cancer vaccines, and other immunotherapy approaches ...

HLA-typing is a simple and widely available test. Tumor Grade: BriaCell has noted clinical benefit in its patients with grade I and grade II tumors, suggesting another subgroup of patients for ...

The major bottleneck is finding targets that are uniquely and homogeneously expressed by cancer cells. Another challenge is that TCR therapeutics must be specific for the target antigen and also ...

A research team led by Prof. SUN Cheng from the University of Science and Technology of China (USTC) of the Chinese Academy of Sciences, along with collaborators from the Agency for Science, ...

Presented updated data from ongoing ALLOHA™ Phase 1 heme trial at the 66th ASH Annual Meeting and ExpositionIND application cleared for seventh ...

they bind to tumor antigens. This can increase receptor sensitivity while reducing cytotoxicity and T cell exhaustion observed with a CAR. 11,12 (8) Synthetic TCR antigen receptor/HLA-independent TCR ...

Plans to file an investigational new drug (IND) application for TSC-102-A0301, a TCR-T targeting CD45 on HLA-A*03:01, in the second half of 2025. Solid Tumor Program: TScan continues to expand the ...